Abstract
Purpose
The purpose of this study was to assess the potential utility of small-molecule apoptotic radiotracer, 2-(5-[18F]fluoropentyl)-2-methyl malonic acid ([18F]ML-10), for positron emission tomography (PET)/computed tomography (CT) monitoring the progression of pulmonary fibrosis in a rat model.
Procedures
Male Sprague-Dawley rats were used to establish a rat model of pulmonary fibrosis by means of bleomycin (BLM) administration; control rats received saline (n = 12 per group). PET/CT with [18F]ML-10 and 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) was performed in two groups at different stages of pulmonary fibrosis. The fibrotic response and the cell apoptosis were assessed with histologic examination. Differences in the apoptosis rate, fibrotic activity, and the lung uptake of [18F]ML-10 and [18F]FDG between two groups were determined with Student t test.
Results
Compared with control group, BLM group showed a higher lung uptake of [18F]ML-10 at all imaging time points (all P < 0.001). During the fibrotic phase of this disease model (days 21 and 28), the lung uptake of [18F]ML-10 was higher than that of [18F]FDG in the BLM group (all P < 0.001). Moreover, accumulation of [18F]ML-10 in the lung tissues increased in proportion to the apoptosis rate (R2 = 0.9863, P < 0.0001) and fibrotic activity (R2 = 0.9631, P < 0.0001) of rat pulmonary fibrosis. Conversely, no correlation between [18F]FDG uptake and fibrotic activity was found.
Conclusions
[18F]ML-10 PET/CT enabled monitoring the progression of rat pulmonary fibrosis, whereas [18F]FDG PET/CT could not. Implications for noninvasive diagnosis of pulmonary fibrosis, assessment of fibrotic activity, and evaluation of antifibrotic therapy are expected.
Similar content being viewed by others
References
King TE Jr, Pardo A, Selman M (2011) Idiopathic pulmonary fibrosis. Lancet 378:1949–1961
Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D (2012) Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 21:355–361
du Bois RM (2010) Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 9:129–140
Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King te Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ, ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824
Raghu G, Anstrom KJ, King TE Jr et al (2012) Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 366:1968–1977
Bondue B, Sherer F, Van Simaeys G et al (2015) PET/CT with [18F]FDG- and [18F]FBEM-labeled leukocytes for metabolic activity and leukocyte recruitment monitoring in a mouse model of pulmonary fibrosis. J Nucl Med 56:127–132
Blodgett TM, Meltzer CC, Townsend DW (2007) PET/CT: form and function. Radiology 242:360–385
Win T, Lambrou T, Hutton BF, Kayani I, Screaton NJ, Porter JC, Maher TM, Endozo R, Shortman RI, Lukey P, Groves AM (2012) [18F]Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials. Eur J Nucl Med Mol Imaging 39:521–528
Ambrosini V, Zompatori M, De Luca F et al (2010) 68Ga-DOTANOC PET/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis: preliminary results. J Nucl Med 51:1950–1955
Wallace WE, Gupta NC, Hubbs AF et al (2002) Cis-4-[18F]fluoro-L-proline PET imaging of pulmonary fibrosis in a rabbit model. J Nucl Med 43:413–420
Umeda Y, Demura Y, Ishizaki T, Ameshima S, Miyamori I, Saito Y, Tsuchida T, Fujibayashi Y, Okazawa H (2009) Dual-time-point [18F]FDG PET imaging for diagnosis of disease type and disease activity in patients with idiopathic interstitial pneumonia. Eur J Nucl Med Mol Imaging 36:1121–1130
El-Chemaly S, Malide D, Yao J et al (2013) Glucose transporter-1 distribution in fibrotic lung disease: association with [18F]-2-fluoro-2-deoxyglucose-PET scan uptake, inflammation, and neovascularization. Chest 143:1685–1691
Groves AM, Win T, Screaton NJ, Berovic M, Endozo R, Booth H, Kayani I, Menezes LJ, Dickson JC, Ell PJ (2009) Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with [18F]FDG PET/CT. J Nucl Med 50:538–545
Meissner HH, Soo Hoo GW, Khonsary SA, Mandelkern M, Brown CV, Santiago SM (2006) Idiopathic pulmonary fibrosis: evaluation with positron emission tomography. Respiration 73:197–202
Lavalaye J, Grutters JC, van de Garde EM et al (2009) Imaging of fibrogenesis in patients with idiopathic pulmonary fibrosis with cis-4-[18F]-Fluoro-L: -proline PET. Mol Imaging Biol 11:123–127
Jones HA, Valind SO, Clark IC, Bolden GE, Krausz T, Schofield JB, Boobis AR, Haslett C (2002) Kinetics of lung macrophages monitored in vivo following particulate challenge in rabbits. Toxicol Appl Pharmacol 183:46–54
Bellani G, Caironi P (2011) Lung imaging during acute respiratory distress syndrome: CT- and PET-scanning. Trends in Anaesthesia and Critical Care 1:203–209
Win T, Screaton NJ, Porter J, Endozo R, Wild D, Kayani I, Dickson J, Shortman RI, Reubi JC, Ell PJ, Groves AM (2012) Novel positron emission tomography/computed tomography of diffuse parenchymal lung disease combining a labeled somatostatin receptor analogue and 2-deoxy-2[18F]fluoro-D-glucose. Mol Imaging 11:91–98
Jones HA, Schofield JB, Krausz T et al (1998) Pulmonary fibrosis correlates with duration of tissue neutrophil activation. Am J Respir Crit Care Med 158:620–628
Taylor RC, Cullen SP, Martin SJ (2008) Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 9:231–241
Fine A, Janssen-Heininger Y, Soultanakis RP, Swisher SG, Uhal BD (2000) Apoptosis in lung pathophysiology. Am J Phys Lung Cell Mol Phys 279:L423–L427
Barbas-Filho JV, Ferreira MA, Sesso A, Kairalla RA, Carvalho CR, Capelozzi VL (2001) Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IFP)/usual interstitial pneumonia (UIP). J Clin Pathol 54:132–138
Reshef A, Shirvan A, Akselrod-Ballin A, Wall A, Ziv I (2010) Small-molecule biomarkers for clinical PET imaging of apoptosis. J Nucl Med 51:837–840
Zhang K, Si XP, Huang J, Han J, Liang X, Xu XB, Wang YT, Li GY, Wang HY, Wang JH (2016) Preventive effects of Rhodiola rosea L. on bleomycin-induced pulmonary fibrosis in rats. Int J Mol Sci 17:879
Tang H, Gao L, Mao J, He H, Liu J, Cai X, Lin H, Wu T (2016) Salidroside protects against bleomycin-induced pulmonary fibrosis: activation of Nrf2-antioxidant signaling, and inhibition of NF-kappaB and TGF-beta1/Smad-2/-3 pathways. Cell Stress Chaperones 21:239–249
Liu S, Nie D, Jiang S, Tang G (2017) Efficient automated synthesis of 2-(5-[18F]fluoropentyl)-2-methylmalonic acid ([18F]ML-10) on a commercial available [18F]FDG synthesis module. Appl Radiat Isot 123:49–53
Ashcroft T, Simpson JM, Timbrell V (1988) Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 41:467–470
Sener G, Topaloglu N, Sehirli AO et al (2007) Resveratrol alleviates bleomycin-induced lung injury in rats. Pulm Pharmacol Ther 20:642–649
Janick-Buckner D, Ranges GE, Hacker MP (1989) Alteration of bronchoalveolar lavage cell populations following bleomycin treatment in mice. Toxicol Appl Pharmacol 100:465–473
Moore BB, Hogaboam CM ((2008)) Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 294:L152–L160
Kadirvel M, Fairclough M, Cawthorne C, Rowling EJ, Babur M, McMahon A, Birkket P, Smigova A, Freeman S, Williams KJ, Brown G (2014) Detection of apoptosis by PET/CT with the diethyl ester of [18F]ML-10 and fluorescence imaging with a dansyl analogue. Bioorg Med Chem 22:341–349
Chopra A (2004) 2-(5-[18F]Fluoro-pentyl)-2-methyl-malonic acid (ML-10), molecular imaging and contrast agent database (MICAD). National Center for Biotechnology Information (US), Bethesda
Funding
This work was supported by the National Natural Science Foundation of China (No. 81571704, No. 81371584, No. 81671719), the Science and Technology Foundation of Guangdong Province (No. 2014A020210008, No. 2013B021800264, No. 2016B090920087), the Science and Technology Planning Project Foundation of Guangzhou (No. 201604020169, No. 201510010145), and the Natural Science Foundation of Guangdong Province (No. 2015A030313067).
Author information
Authors and Affiliations
Contributions
Xianhong Xiang and Ganghua Tang had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Ying Xiong and Dahong Nie contributed to designing this study, collecting samples, carrying out experiments, and writing the manuscript. Shaoyu Liu, Hui Ma, and Shu Su contributed to collecting samples and revising the manuscript. Aixia Sun, Jing Zhao, and Zhanwen Zhang contributed to revising the manuscript. All authors have approved the final article.
Corresponding authors
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Xiong, Y., Nie, D., Liu, S. et al. Apoptotic PET Imaging of Rat Pulmonary Fibrosis with Small-Molecule Radiotracer. Mol Imaging Biol 21, 491–499 (2019). https://doi.org/10.1007/s11307-018-1242-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-018-1242-7